Corona Remedies Shares Soar 38% on Listing, IPO Investors Cheer

• Corona Remedies shares listed at ₹1,452 on BSE and ₹1,470 on NSE, providing IPO investors with about a 38% listing gain from the ₹1,062 upper price band.
• The company's ₹655.37 crore IPO, open from Dec 8-10, was significantly oversubscribed by 144.54 times.
• Established in 2004, Corona Remedies is a pharmaceutical company focusing on women's health, cardiology, pain management, and urology, with 71 brands by June 2025.
• Corona Remedies has shown strong financial performance, with net profit growing to ₹149.43 crore in FY2025 and total income exceeding ₹1202.35 crore at over 16% CAGR.

Why It Matters: Corona Remedies' IPO success reflects high investor returns and robust company financials.